Schizophrenia Daily News Blog

Lundbeck launches new schizophrenia drug in Europe

H. Lundbeck A/S today announced that Serdolect® (sertindole) is now available in the first country in Europe – Estonia. This is the first launch of Serdolect®, which received marketing approval for the treatment of schizophrenia from the European Commission on 20 December 2005. Serdolect® is expected to be launched in a number of countries among others the Scandinavian countries and in Germany in the first half of 2006 and in more than 15 other countries during 2006 and 2007.

Serdolect was granted marketing approval for the treatment of schizophrenia by the European Commission on December 20, 2005.

About Serdolect®
Serdolect® is an effective antipsychotic drug for the treatment of schizophrenia without sedative effect and with placebo level extra pyramidal symptoms. Serdolect® has an inhibitory effect on central dopamine D2 and serotonin 5HT2 receptors as well as on alpha-adrenergic receptors.

Since the 1990s, the efficacy and safety of using Serdolect® has been evaluated in numerous studies including more than 17,000 patients.

Since CHMP’s (Committee for Medicinal Products for Human Use, under EMEA) temporary suspension of the marketing authorisation for Serdolect® in 1998, Lundbeck has included an additional 5,000 patients in a study confirming that Serdolect® can be prescribed safely.

Serdolect® derives from Lundbeck’s in-house research, and the company holds the global rights.

Source: Lundbeck, AS